| Literature DB >> 35309536 |
Miroslav Petr1, Dan Thiel2, Kvapilová Kateřina2,3, Petr Brož2,4, Tomáš Malý1, František Zahálka1, Pavlína Vostatková1, Michal Wilk5, Jakub Chycki5, Petr Stastny1.
Abstract
Heritability studies on sport-related traits accepted that endurance, speed, power, and strength abilities include an active genetic predisposition to elite soccer participation. This study evaluates the influence of selected genetic variants on performance in speed, power, and strength laboratory tests on a group of elite soccer players, including their playing position. A ninety-nine male elite soccer players were compared to controls (n = 107) and tested for quadriceps and hamstrings isokinetic strength at speed 60°/s, 180°/s, and 300°/s, jump performance, and genotypes of ACTN3 (R577X, rs1815739), ACE (I/D, rs1799752), NOS3 (Glu298Asp, rs1799983), AMPD1 (34C/T, rs17602729), UCP2 (Ala55Val, rs660339), BDKRB2 (+9/-9, rs5810761) and IL1RN (VNTR 86-bp). The ACTN3 XX homozygotes in defenders had lower quadriceps and hamstring isokinetic strength in all tested speeds than ACTN3 RX and RR genotypes (p < 0.05). The ACTN3 RR homozygotes in defenders had higher quadriceps strength in all tested velocities than the RX heterozygotes (p < 0.05). We also found other associations between playing-position in soccer and increased strength of lower limbs for AMPD1 CC and NOS3 Glu/Glu genotypes, and IL1RN*2 allele carriers. Total genetic score regression explained 26% of the variance in jump performance and isokinetic strength. The ACTN3 R allele, NOS3 Glu/Glu genotypes, and IL1RN*2 allele pre-disposed the attackers and defenders playing position in elite soccer, where those positions have higher strength and power measures than midfielders. Midfielders have lower strength and power conditions than other playing positions without relation to strength and power genes.Entities:
Keywords: Football; Isokinetic; Jump; Muscle strength; Performance; Sport genomic
Year: 2021 PMID: 35309536 PMCID: PMC8919892 DOI: 10.5114/biolsport.2022.105333
Source DB: PubMed Journal: Biol Sport ISSN: 0860-021X Impact factor: 2.806
Total genetic score counts for each examined genotype.
| Genotype | Total genetic score count |
|---|---|
| 0 = II, 1 = ID, 2 = DD | |
| 0 = XX, 1 = RX, 2 = RR | |
| 0 = +9 + 9, 1 = +9 – 9, 2 = –9 – 9 | |
| 0 = Asp/Asp, 1 = Glu/Asp, 2 = Glu/Glu | |
| 0 = TT, 1 = CT, 2 = CC | |
| 0 = CC, 1 = CT, 2 = TT | |
| 0 = 1/1 or 1/3, 1 = 1/2 or 2/3, 2 = 2/ 2 |
FIG. 1Quadriceps and hamstring strength for ACTN3 R577X genotypes and speeds of contraction in soccer player positions.
†Significantly higher than other genotype groups at defined playing position and speed of contraction. †† significantly higher than other genotypes groups at all speeds of contraction regardless of playing-position. *Significantly lower than other genotype groups at defined playing position and speed of contraction. ** Significantly lower than other genotypes groups at all speeds of contraction regardless of playing position. ‡ Significantly lower than other genotype groups in midfielders at 300° speed of contraction. Significance is according to ANOVA and HSD test.
Allele and genotype frequencies Chi-square comparison for the soccer players and the controls.
| Genotype / allele / comparison type | Defenders | Attackers | Goalkeepers | Midfielders | All | Controls | ||
|---|---|---|---|---|---|---|---|---|
| n 31 | 15 | 14 | 39 | 99 | 107 | |||
| ACTN3 R577X | Allele n (%) | R | 35 (56.5) | 22 (73.3) | 14 (50.0) | 47 (60.2) | 118 (59.6) | 128 (59.8) |
| X | 27 (43.5) | 8 (26.7) | 14 (50.0) | 31 (39.7) | 80 (40.4) | 86 (40.2) | ||
|
| Compared to controls | 0.636 | 0.154 | 0.321 | 0.945 | 0.964 | - | |
|
| Compared to all | 0.661 | 0.150 | 0.335 | 0.920 | - | - | |
| Genotype n (%) | RR | 10 (32.3) | 7 (46.7) | 5 (35.7) | 12 (30.8) | 34 (34.3) | 36 (33.6) | |
| RX | 15 (48.4) | 8 (53.3) | 4 (28.6) | 23 (59.0) | 50 (50.5) | 56 (52.3) | ||
| XX | 6 (19.4) | 0 (0) | 5 (35.7) | 4 (10.3) | 15 (15.2) | 15 (14.0) | ||
|
| Compared to controls | 0.765 | 0.254 | 0.840 | 0.735 | 0.958 | - | |
|
| Compared to all | 0.857 | 0.241 | 0.124 | 0.615 | - | - | |
| ACE I/D | Allele n (%) | I | 35 (56.5) | 17 (56.7) | 13 (46.4) | 39 (50.0) | 104 (52.5) | |
| D | 27 (43.5) | 13 (43.3) | 15 (53.6) | 39 (50.0) | 94 (47.5) | |||
|
| Compared to controls | |||||||
|
| Compared to all | 0.589 | 0.672 | 0.546 | 0.705 | - | ||
| Genotype n (%) | II | 8 (25.8) | 4 (26.7) | 2 (14.3) | 10 (25.6) | 24 (24.2) | ||
| ID | 19 (61.3) | 9 (60.0) | 9 (64.3) | 19 (48.7) | 56 (56.6) | |||
| DD | 4 (12.9) | 2 (13.3) | 3 (21.4) | 10 (25.6) | 19 (19.2) | |||
|
| Compared to controls | |||||||
|
| Compared to all | 0.725 | 0.860 | 0.709 | 0.640 | - | ||
| NOS3 Glu298Asp | Allele n (%) | Glu | 51 (82.3) | 24 (80.0) | 22 (78.6) | 54 (69.2) | 151 (76.3) | 146 (68.2) |
| Asp | 11 (17.7) | 6 (20.0) | 6 (21.4) | 24 (30.8) | 47 (23.7) | 68 (31.8) | ||
|
| Compared to controls | 0.031 | 0.189 | 0.264 | 0.870 | 0.069 | - | |
|
| Compared to all | 0.322 | 0.652 | 0.787 | 0.229 | - | - | |
| Genotype n (%) | Glu/Glu | 21 (67.7) | 9 (60.0) | 8 (57.1) | 18 (46.2) | 56 (56.6) | 48 (44.9) | |
| Glu/Asp | 9 (29.0) | 6 (40.0) | 6 (42.9) | 18 (46.2) | 39 (39.4) | 50 (46.7) | ||
| Asp/Asp | 1 (3.2) | 0 (0) | 0 (0) | 3 (7.7) | 4 (4.0) | 9 (8.4) | ||
|
| Compared to controls | 0.075 | 0.361 | 0.445 | 0.985 | 0.166 | - | |
|
| Compared to all | 0.542 | 0.728 | 0.740 | 0.447 | - | - | |
| AMPD1 34C/T | Allele n (%) | C | 52 (83.9) | 26 (86.7) | 25 (89.3) | 69 (88.5) | 172 (86.9) | 179 (83.6) |
| T | 10 (16.1) | 4 (13.3) | 3 (10.7) | 9 (11.5) | 26 (13.1) | 35 (16.4) | ||
|
| Compared to controls | 0.966 | 0.672 | 0.440 | 0.309 | 0.357 | - | |
|
| Compared to all | 0.551 | 0.976 | 0.720 | 0.720 | - | - | |
| Genotype n (%) | C/C | 21 (67.7) | 11 (73.3) | 11 (78.6) | 30 (76.9) | 73 (73.7) | 76 (71.0) | |
| C/T | 10 (32.3) | 4 (26.7) | 3 (21.4) | 9 (23.1) | 26 (26.3) | 27 (25.2) | ||
| T/T | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0.0) | 4 (3.7) | ||
|
| Compared to controls | 0.441 | 0.748 | 0.707 | 0.439 | 0.152 | - | |
|
| Compared to all | 0.515 | 0.974 | 0,698 | 0.699 | - | - | |
| UCP2 Vla55Val | Allele n (%) | Ala | 38 (61.3) | 20 (66.7) | 13 (46.4) | 41 (52.6) | 112 (56.6) | 126 (58.9) |
| Val | 24 (38.7) | 10 (33.3) | 15 (53.6) | 37 (47.4) | 86 (43.4) | 88 (41.1) | ||
|
| Compared to controls | 0.733 | 0.415 | 0.210 | 0.335 | 0.635 | - | |
|
| Compared to all | 0.511 | 0.296 | 0.313 | 0.547 | - | - | |
| Genotype n (%) | Ala/Ala | 10 (32.3) | 6 (40.0) | 4 (28.6) | 9 (23.1) | 29 (23.3) | 37 (34.6) | |
| Ala/Val | 18 (58.1) | 8 (53.3) | 5 (35.7) | 23 (59.0) | 54 (54.5) | 52 (48.6) | ||
| Val/Val | 3 (9.7) | 1 (6.7) | 5 (35.7) | 7 (17.9) | 16 (16.2) | 18 (16.8) | ||
|
| Compared to controls | 0.530 | 0.594 | 0.235 | 0.402 | 0.665 | - | |
|
| Compared to all | 0.670 | 0.528 | 0.187 | 0.762 | - | - | |
| BDKRB2 +9/-9 | Allele n (%) | + 9 | 32 (51.6) | 15 (50.0) | 11 (39.3) | 36 (46.2) | 94 (47.5) | |
| -9 | 30 (48.4) | 15 (50.0) | 17 (60.7) | 42 (53.8) | 104 (52.5) | |||
|
| Compared to controls | |||||||
|
| Compared to all | 0.569 | 0.796 | 0.416 | 0.843 | - | ||
| Genotype n (%) | + 9/+9 | 9 (29.0) | 3 (20.0) | 1 (7.1) | 10 (25.6) | 23 (23.2) | ||
| +9/-9 | 14 (45.2) | 9 (60.0) | 9 (64.3) | 16 (41.0) | 48 (48.5) | |||
| -9/-9 | 8 (25.8) | 3 (20.0) | 4 (28.6) | 13 (33.3) | 28 (28.3) | |||
|
| Compared to controls | |||||||
|
| Compared to all | 0.807 | 0.693 | 0.350 | 0.725 | - | ||
| IL-1RN (VNTR 86-bp) | Allele (%) |
| 39 (62.9) | 21 (70,0) | 23 (82.1) | 56 (71.8) | ||
|
| 23 (37.1) | 9 (30,0) | 5 (17.9) | 22 (28.2) | ||||
|
| Compared to controls | |||||||
|
| Compared to all | 0.280 | 0.982 | 0.189 | 0.794 | |||
| Genotype (%) |
| 11 (35.5) | 8 (53,3) | 9 (64.3) | 21 (53.8) | |||
|
| 17 (54.8) | 5 (33.3) | 5 (35.7) | 14 (35.9) | ||||
|
| 3 (9.7) | 2 (13.3) | 0 (0) | 4 (10.3) | ||||
|
| Compared to controls | |||||||
|
| Compared to all |
|
|
|
| |||
p = the “p” values of the Chi-square test
statistically significant difference according to the Chi-square test.
FIG. 2Quadriceps and hamstring strength for AMPD1 C34T genotypes at high contraction speed.
*Significantly lower than other genotypes in the playing position. ** Significantly lower than different genotypes regardless of playing position. Significance is according to ANOVA and HSD test.
FIG. 3Quadriceps strength for NOS3 Glu298Asp genotypes and speeds of contraction in soccer player positions.
*Significantly higher than other genotypes in the playing position according to ANOVA and HSD test.
FIG. 4Quadriceps and hamstring strength for IL1RN genotypes and speeds of contraction in soccer player positions.
*Significantly higher than other genotypes in the playing position according to ANOVA and HSD test.
The multiple backward regression for correlated phenotypes in all analyzed genes (TGS) and four significant genotypes (TGSsig).
| Phenotypes | SE | t | p | ||
|---|---|---|---|---|---|
|
| Whole model | 2.25 | 0.31 | 10.02 | 0.005 |
| 0,15 | 0.14 | 2.21 | 0.030 | ||
| 0,22 | 0.18 | 2.54 | 0.013 | ||
| 0,38 | 0.14 | 4.20 | 0.001 | ||
| 0,24 | 0.16 | 2.61 | 0.011 | ||
| 0,18 | 0.13 | 1.60 | 0.112 | ||
| 0,19 | 0.16 | 2.32 | 0.023 | ||
| 0,12 | 0.15 | 1.62 | 0.109 | ||
| TGS | -0,02 | 0.28 | -2.07 | 0.042 | |
|
| Whole model | 2,50 | 0,20 | 12,68 | < 0,001 |
| 0,32 | 0,10 | 3,37 | < 0,001 | ||
| 0,16 | 0,09 | 1,76 | 0,083 | ||
| 0,14 | 0,11 | 1,27 | 0,209 | ||
| 0,09 | 0,08 | 1,09 | 0,277 | ||
| TGSsig | -0,01 | 0,00 | -1,17 | 0,246 |
SE = standard error
explained phenotype variance R2 = 0.26, p = 0.005
explained phenotype variance R2 = 0.19, p = 0.009.
The characteristic of the subjects
| All soccer players: | 99 |
|---|---|
| – Goalkeepers | 14 |
| – Defenders | 31 |
| – Midfielders | 39 |
| – Attackers | 15 |
| Age (y) | 25.4 ± 4.51 |
| Height (cm) | 181.4 ± 6.11 |
| Weight (kg) | 77.4 ± 7.22 |
Quantity of the components used for the PCR
| Genotype | DNA (μl) | DNA polymerase (μl) | Attackers primer/reverse primer (μl) | Buffer (μl) | dNTP (μl) | MgCl2 (μl) | Distilled H2O (μl) | Betain (μl) |
|---|---|---|---|---|---|---|---|---|
| 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 | |
| 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 | |
| 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 | |
| 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 | |
| 2 | Taq(5U/μl) 0,9 | 0,8 | 10xTaq Buffer with KCl 2,0 | 1,5 | 25mM MgCl21,6 | 6,4 | 4 | |
| 2 | Taq(5U/μl) 0,4 | F 0,8 R 3,2 | 10xTaq Buffer with KCl 2,0 | 6 | 25mM MgCl21,6 | / | 4 | |
| 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 |
Forward/reverse primers and PCR conditions for the examined genotypes
| Genotype | Forward primer (5’–3’) | Reverse primer (5’–3’) | PCR reaction conditions | ||
|---|---|---|---|---|---|
| Denaturation | Annealing and cycles | Final extension | |||
| CTGGAGAGCCACTCCCATCCTTTCT | GACGTGGCCATCACATTCGTCAGAT | 98°C 30 s 98°C 10 s | 63°C 30 s – 35 cycles 72°C 30 s | 72°C 5 min | |
| CTGTTGCCTGTGGTAAGTGGG | TGGTCACAGTATGCAGGAGGG | 94°C 30 s | 70°C 1 min – 35 cycles | 72°C 10 min | |
| TCCAGCTCTGGCTTCTGG | AGTCGCTCCCTGGTACTGC | 98°C 30 s 98°C 10 s | 68°C 30 s – 35 cycles 72°C 30 s | 72°C 5 min | |
| CATGAGGCTCAGCCCCAGAAC | AGTCAATCCCTTTGGTGCTCAC | 98°C 30 s 98°C 10 s | 62°C 30 s – 35 cycles 72°C 10 s | 72°C 5 min | |
| CTTCATACAGCTGAAGAGACA | GAATCCAGAAAAGCCATGAGC | 95°C 30 s | 56,4°C 1 min 72°C 30 s – 45 cycles | 72°C 5 min | |
| TGGGAGTCTTGATGGTGTCTAC | CACCGCGGTACTGGGCGCTG | 95°C 30 s | 61,2°C 50 s 72°C 30 s – 46 cycles | 72°C 5 min | |
| CTCAGCAACACTCCTAT | TCCTGGTCTGCAGGTAA | 98°C 30 s | 57°C 30 s 72°C 30 s – 35 cycles | 72°C 5 min | |